160 East 53rd StreetNew York, NY 10022
Overview of Dr. D'Angelo
Dr. Sandra D'Angelo is an oncologist based in New York, specializing in hematologic oncology and sarcoma. She completed her fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center and her residency in Internal Medicine at NYU Grossman School of Medicine. Her research interests include immunotherapy and various cancers, such as Merkel cell carcinoma and sarcoma. Dr. D'Angelo has multiple publications on treatments and outcomes related to these cancers, some of which have been cited extensively. She is actively involved in clinical trials focusing on a range of treatments for cancers like Merkel cell carcinoma and soft tissue sarcoma.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
PA State Medical License 2024 - 2026
NJ State Medical License 2019 - 2025
NY State Medical License 2005 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
- Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Start of enrollment: 2019 Aug 13
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2020 Sep 29
- Join now to see all
Publications & Presentations
PubMed
- 89 citationsClinical genomic profiling in the management of patients with soft tissue and bone sarcoma.Mrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, Victoria Robinson, Richard A Ferraro
Nature Communications. 2022-06-15 - 28 citationsAvelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upSandra P. D'Angelo, Shailender Bhatia, A.S. Brohl, Omid Hamid, Janice M. Mehnert
ESMO Open. 2021-10-26 - 7 citationsCase Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases.Edmund K. Bartlett, Sandra P. D'Angelo, Ciara Marie Kelly, Robert H Siegelbaum, Charles Fisher
Frontiers in Oncology. 2021-10-15
Lectures
- Pilot study of NKTR214 and nivolumab in patients with sarcomas.2019 ASCO Annual Meeting - 6/1/2019
- Desmoid Tumors Biology: Exploiting Estrogen and Notch Signaling2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
T-cell Therapy Shows Promise in Rare SarcomasNovember 12th, 2021
Immunotherapy Jumps Ahead of Chemotherapy in Advanced Merkel Cell CarcinomaApril 5th, 2019
Grant Support
- Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcomaSLOAN-KETTERING INST CAN RESEARCH2022–2026
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPOHumana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
